Availability of Draft Toxicological Profiles: Antimony; 2,4-D; Molybdenum; Silica, 27066-27067 [2017-12161]

Download as PDF nlaroche on DSK30NT082PROD with NOTICES 27066 Federal Register / Vol. 82, No. 112 / Tuesday, June 13, 2017 / Notices Regulatory Affairs, Office of Management and Budget, Attention: Desk Officer for the Federal Trade Commission, New Executive Office Building, Docket Library, Room 10102, 725 17th Street NW., Washington, DC 20503. Comments sent to OMB by U.S. postal mail are subject to delays due to heightened security precautions. Thus, comments instead can also be sent via email to wliberante@omb.eop.gov. Because your comment will be placed on the publicly accessible FTC Web site at https://www.ftc.gov/, you are solely responsible for making sure that your comment does not include any sensitive or confidential information. In particular, your comment should not include any sensitive personal information, such as your or anyone else’s Social Security number; date of birth; driver’s license number or other state identification number, or foreign country equivalent; passport number; financial account number; or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, such as medical records or other individually identifiable health information. In addition, your comment should not include any ‘‘trade secret or any commercial or financial information which . . . is privileged or confidential’’—as provided by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)— including in particular competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names. Comments containing material for which confidential treatment is requested must be filed in paper form, must be clearly labeled ‘‘Confidential,’’ and must comply with FTC Rule 4.9(c). In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c). Your comment will be kept confidential only if the General Counsel grants your request in accordance with the law and the public interest. Once your comment has been posted on the public FTC Web site—as legally required by FTC Rule 4.9(b)—we cannot redact or remove your comment from the FTC Web site, unless you submit a confidentiality request that meets the requirements for such treatment under FTC Rule 4.9(c), and the General Counsel grants that request. VerDate Sep<11>2014 14:58 Jun 12, 2017 Jkt 241001 Visit the FTC Web site to read this Notice. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before July 13, 2017. For information on the Commission’s privacy policy, including routine uses permitted by the Privacy Act, see https://www.ftc.gov/ site-information/privacy-policy. David C. Shonka, Acting General Counsel. [FR Doc. 2017–12191 Filed 6–12–17; 8:45 am] BILLING CODE 6750–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Toxic Substances and Disease Registry [Docket No. ATSDR–2014–0002] Availability of Draft Toxicological Profiles: Antimony; 2,4-D; Molybdenum; Silica Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS). ACTION: Notice of availability, and request for comment. AGENCY: The Agency for Toxic Substances and Disease Registry (ATSDR), within the Department of Health and Human Services (HHS) announces the availability of Toxicological Profiles for review and comment. All toxicological profiles issued as ‘‘Drafts for Public Comment’’ represent ATSDR’s best efforts to provide important toxicological information on priority hazardous substances. ATSDR is seeking public comments and additional information or reports on studies about the health effects of these four substances for review and potential inclusion in the profiles. Although ATSDR considers key studies for these substances during the profile development process, this document solicits any relevant, additional studies. ATSDR will evaluate the quality and relevance of such data or studies for possible inclusion into the profile. ATSDR remains committed to providing a public comment period for these documents as a means to best serve public health and the public. DATES: Comments must be submitted by September 11, 2017. SUMMARY: PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 You may submit comments, identified by docket number ATSDR– 2014–0002, by any of the following methods: • Internet: Access the Federal eRulemaking Portal at www.regulations.gov. Follow the instructions for submitting comments. • Mail: Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Rd. NE., MS F–57, Atlanta, GA 30329. Instructions: All submissions must include the agency name and docket number for this notice. All relevant comments will be posted without change. This means that no confidential business information or other confidential information should be submitted in response to this notice. FOR FURTHER INFORMATION CONTACT: Commander Jessilynn B. Taylor, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Rd. NE., MS F–57, Atlanta, GA 30329, Email: jxt1@cdc.gov; Phone: 770–488–3313. SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain requirements for ATSDR and the U.S. Environmental Protection Agency (EPA) regarding hazardous substances that are most commonly found at facilities on the CERCLA National Priorities List (NPL). Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare toxicological profiles for each substance included on the priority list of hazardous substances [also called the Substance Priority List (SPL)]. This list identifies 275 hazardous substances that ATSDR and EPA have determined pose the most significant potential threat to human health. The SPL is available online at www.atsdr.cdc.gov/spl. In addition, CERCLA provides ATSDR with the authority to prepare toxicological profiles for substances not found on the SPL. CERCLA authorizes ATSDR to establish and maintain inventory of literature, research, and studies on the health effects of toxic substances (CERCLA Section 104(i)(1)(B)); to respond to requests for health consultations (CERCLA Section 104(i)(4)); and to support the sitespecific response actions conducted by the agency. ADDRESSES: E:\FR\FM\13JNN1.SGM 13JNN1 Federal Register / Vol. 82, No. 112 / Tuesday, June 13, 2017 / Notices Availability The Draft Toxicological Profiles are available online at http:// www.atsdr.cdc.gov/ToxProfiles and at www.regulations.gov, Docket No. ATSDR–2014–0002. Pamela I. Protzel Berman, Director, Office of Policy, Planning and Evaluation, Agency for Toxic Substances and Disease Registry. [FR Doc. 2017–12161 Filed 6–12–17; 8:45 am] BILLING CODE 4163–70–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–3343–PN] Medicare and Medicaid Programs: Application From the American Osteopathic Association/Healthcare Facilities Accreditation Program (AOA–HFAP) for Continued CMS Approval of Its Ambulatory Surgical Center Accreditation Program Centers for Medicare and Medicaid Services, HHS. ACTION: Notice with request for comment. AGENCY: This proposed notice acknowledges the receipt of an application from the American Osteopathic Association/Healthcare Facilities Accreditation Program (AOA– HFAP) for continued recognition as a national accrediting organization for Ambulatory Surgical Centers that wish to participate in the Medicare or Medicaid programs. DATES: To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on July 13, 2017. ADDRESSES: In commenting, please refer to file code CMS–3343–PN. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. You may submit comments in one of four ways (please choose only one of the ways listed): 1. Electronically. You may submit electronic comments on this regulation to http://www.regulations.gov. Follow the ‘‘Submit a comment’’ instructions. 2. By regular mail. You may mail written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–3343–PN, P.O. Box 8010, Baltimore, MD 21244–8010. nlaroche on DSK30NT082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 14:58 Jun 12, 2017 Jkt 241001 Please allow sufficient time for mailed comments to be received before the close of the comment period. 3. By express or overnight mail. You may send written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–3343–PN, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850. 4. By hand or courier. Alternatively, you may deliver (by hand or courier) your written comments ONLY to the following addresses: a. For delivery in Washington, DC— Centers for Medicare & Medicaid Services, Department of Health and Human Services, Room 445–G, Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201. (Because access to the interior of the Hubert H. Humphrey Building is not readily available to persons without Federal government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons wishing to retain a proof of filing by stamping in and retaining an extra copy of the comments being filed.) b. For delivery in Baltimore, MD— Centers for Medicare & Medicaid Services, Department of Health and Human Services, 7500 Security Boulevard, Baltimore, MD 21244–1850. If you intend to deliver your comments to the Baltimore address, call telephone number (410) 786–9994 in advance to schedule your arrival with one of our staff members. Comments erroneously mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period. For information on viewing public comments, see the beginning of the SUPPLEMENTARY INFORMATION section. FOR FURTHER INFORMATION CONTACT: Monda Shaver, (410) 786–0310, Erin McCoy, (410) 786–2337, or Patricia Chmielewski, (410) 786–6899. SUPPLEMENTARY INFORMATION: Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following Web site as soon as possible after they have been received: http:// www.regulations.gov. Follow the search PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 27067 instructions on that Web site to view public comments. Comments received timely will also be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, at the headquarters of the Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, Maryland 21244, Monday through Friday of each week from 8:30 a.m. to 4 p.m. To schedule an appointment to view public comments, phone 1–800–743–3951. I. Background Under the Medicare program, eligible beneficiaries may receive covered services from an Ambulatory Surgical Center (ASC) provided certain requirements are met. Section 1832(a)(2)(F)(i) of the Social Security Act (the Act) establishes distinct criteria for facilities seeking designation as an ASC. Regulations concerning provider agreements are at 42 CFR part 489 and those pertaining to activities relating to the survey and certification of facilities are at 42 CFR part 488. The regulations at 42 CFR part 416 specify the conditions that an ASC must meet in order to participate in the Medicare program, the scope of covered services, and the conditions for Medicare payment for ASCs. Generally, to enter into an agreement, an ASC must first be certified by a State survey agency as complying with the conditions or requirements set forth in part 416 of our Medicare regulations. Thereafter, the ASC is subject to regular surveys by a State survey agency to determine whether it continues to meet these requirements. Section 1865(a)(1) of the Act provides that, if a provider entity demonstrates through accreditation by a Centers for Medicare & Medicaid Services (CMS) approved national accrediting organization (AO) that all applicable Medicare conditions are met or exceeded, we may deem those provider entities as having met the requirements. Accreditation by an AO is voluntary and is not required for Medicare participation. If an AO is recognized by the Secretary of the Department of Health and Human Services as having standards for accreditation that meet or exceed Medicare requirements, any provider entity accredited by the national accrediting body’s approved program may be deemed to meet the Medicare conditions. An AO applying for approval of its accreditation program under part 488, subpart A, must provide CMS with reasonable assurance that the AO requires the accredited provider E:\FR\FM\13JNN1.SGM 13JNN1

Agencies

[Federal Register Volume 82, Number 112 (Tuesday, June 13, 2017)]
[Notices]
[Pages 27066-27067]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12161]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[Docket No. ATSDR-2014-0002]


Availability of Draft Toxicological Profiles: Antimony; 2,4-D; 
Molybdenum; Silica

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), 
Department of Health and Human Services (HHS).

ACTION: Notice of availability, and request for comment.

-----------------------------------------------------------------------

SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR), 
within the Department of Health and Human Services (HHS) announces the 
availability of Toxicological Profiles for review and comment. All 
toxicological profiles issued as ``Drafts for Public Comment'' 
represent ATSDR's best efforts to provide important toxicological 
information on priority hazardous substances. ATSDR is seeking public 
comments and additional information or reports on studies about the 
health effects of these four substances for review and potential 
inclusion in the profiles.
    Although ATSDR considers key studies for these substances during 
the profile development process, this document solicits any relevant, 
additional studies. ATSDR will evaluate the quality and relevance of 
such data or studies for possible inclusion into the profile. ATSDR 
remains committed to providing a public comment period for these 
documents as a means to best serve public health and the public.

DATES: Comments must be submitted by September 11, 2017.

ADDRESSES: You may submit comments, identified by docket number ATSDR-
2014-0002, by any of the following methods:
     Internet: Access the Federal eRulemaking Portal at 
www.regulations.gov. Follow the instructions for submitting comments.
     Mail: Division of Toxicology and Human Health Sciences, 
Agency for Toxic Substances and Disease Registry, 1600 Clifton Rd. NE., 
MS F-57, Atlanta, GA 30329.
    Instructions: All submissions must include the agency name and 
docket number for this notice. All relevant comments will be posted 
without change. This means that no confidential business information or 
other confidential information should be submitted in response to this 
notice.

FOR FURTHER INFORMATION CONTACT: Commander Jessilynn B. Taylor, 
Division of Toxicology and Human Health Sciences, Agency for Toxic 
Substances and Disease Registry, 1600 Clifton Rd. NE., MS F-57, 
Atlanta, GA 30329, Email: jxt1@cdc.gov; Phone: 770-488-3313.

SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization 
Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA 
or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain 
requirements for ATSDR and the U.S. Environmental Protection Agency 
(EPA) regarding hazardous substances that are most commonly found at 
facilities on the CERCLA National Priorities List (NPL). Among these 
statutory requirements is a mandate for the Administrator of ATSDR to 
prepare toxicological profiles for each substance included on the 
priority list of hazardous substances [also called the Substance 
Priority List (SPL)]. This list identifies 275 hazardous substances 
that ATSDR and EPA have determined pose the most significant potential 
threat to human health. The SPL is available online at 
www.atsdr.cdc.gov/spl.
    In addition, CERCLA provides ATSDR with the authority to prepare 
toxicological profiles for substances not found on the SPL. CERCLA 
authorizes ATSDR to establish and maintain inventory of literature, 
research, and studies on the health effects of toxic substances (CERCLA 
Section 104(i)(1)(B)); to respond to requests for health consultations 
(CERCLA Section 104(i)(4)); and to support the site-specific response 
actions conducted by the agency.

[[Page 27067]]

Availability

    The Draft Toxicological Profiles are available online at http://www.atsdr.cdc.gov/ToxProfiles and at www.regulations.gov, Docket No. 
ATSDR-2014-0002.

Pamela I. Protzel Berman,
Director, Office of Policy, Planning and Evaluation, Agency for Toxic 
Substances and Disease Registry.
[FR Doc. 2017-12161 Filed 6-12-17; 8:45 am]
 BILLING CODE 4163-70-P